See more : Nishio Rent All Co., Ltd. (9699.T) Income Statement Analysis – Financial Results
Complete financial analysis of Collegium Pharmaceutical, Inc. (COLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Collegium Pharmaceutical, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Global SPAC Partners Co. (GLSPW) Income Statement Analysis – Financial Results
- First Acceptance Corporation (FACO) Income Statement Analysis – Financial Results
- Emera Incorporated (ERRAF) Income Statement Analysis – Financial Results
- Kuala Lumpur Kepong Berhad (2445.KL) Income Statement Analysis – Financial Results
- Silver Elephant Mining Corp. (SILEF) Income Statement Analysis – Financial Results
Collegium Pharmaceutical, Inc. (COLL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.collegiumpharma.com
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 566.77M | 463.93M | 276.87M | 310.02M | 296.70M | 280.41M | 28.48M | 1.71M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 240.60M | 254.45M | 126.25M | 130.18M | 193.66M | 165.68M | 2.60M | 213.00K | 171.00K | 0.00 | 0.00 |
| Gross Profit | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.50M | -171.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 57.55% | 45.15% | 54.40% | 58.01% | 34.73% | 40.92% | 90.89% | 87.55% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.98M | 14.96M | 14.16M |
| General & Administrative | 151.80M | 160.44M | 114.77M | 108.46M | 0.00 | 0.00 | 0.00 | 0.00 | 18.93M | 2.71M | 1.89M |
| Selling & Marketing | 7.41M | 11.74M | 4.19M | 5.37M | 116.45M | 126.76M | 92.76M | 80.63M | 0.00 | 0.00 | 0.00 |
| SG&A | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -94.00K | -348.00K | 0.00 | 0.00 |
| Operating Expenses | 159.21M | 176.17M | 128.41M | 123.60M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.67M | 16.04M |
| Cost & Expenses | 399.81M | 430.61M | 254.66M | 253.78M | 320.45M | 301.10M | 103.92M | 95.79M | 26.91M | 17.67M | 16.04M |
| Interest Income | 15.62M | 1.05M | 12.00K | 232.00K | 1.94M | 1.69M | 582.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 83.34M | 63.21M | 21.01M | 28.88M | 909.00K | 20.13M | 582.00K | 94.00K | 439.00K | 252.00K | 76.00K |
| Depreciation & Amortization | 149.26M | 134.39M | 68.94M | 61.61M | 15.80M | 110.91M | 594.00K | 655.00K | 171.00K | 187.00K | 169.00K |
| EBITDA | 308.33M | 168.76M | 86.58M | 118.07M | -6.02M | 91.91M | -74.27M | -93.43M | -26.65M | -17.48M | -15.95M |
| EBITDA Ratio | 54.40% | 7.41% | 8.02% | 18.21% | -7.35% | -6.78% | -262.86% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Operating Income | 166.96M | -104.57M | -46.70M | -5.09M | -23.75M | -20.69M | -75.45M | -94.08M | -26.91M | -17.67M | -16.04M |
| Operating Income Ratio | 29.46% | -22.54% | -16.87% | -1.64% | -8.00% | -7.38% | -264.95% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -91.23M | -62.17M | -21.00M | -28.65M | 1.03M | -18.44M | 582.00K | -94.00K | -348.00K | -252.00K | -155.00K |
| Income Before Tax | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Income Before Tax Ratio | 13.36% | -6.22% | -1.22% | 8.90% | -7.66% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 27.58M | -3.85M | -74.89M | 830.00K | -14.57M | -110.91M | -1.16M | 94.00K | -91.00K | 252.00K | 79.00K |
| Net Income | 48.16M | -25.00M | 71.52M | 26.75M | -8.15M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Net Income Ratio | 8.50% | -5.39% | 25.83% | 8.63% | -2.75% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| EPS | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| EPS Diluted | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| Weighted Avg Shares Out | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Weighted Avg Shares Out (Dil) | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2023 financial...
Collegium Pharmaceutical, Inc. (COLL) Q1 2023 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer -...
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023 financial...
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
COLL vs. ZTS: Which Stock Is the Better Value Option?
Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations at Collegium Pharmaceuticals Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial...
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
COLL or ZTS: Which Is the Better Value Stock Right Now?
COLL vs. ZTS: Which Stock Is the Better Value Option?
Find 'Strong Buy' Stocks Near their Highs for February
Let's explore a Zacks screen that helps investors find 'Strong Buy' stocks trading near their highs as we head into February
5 Stocks With Recent Price Strength Amid January Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MELI, ACLS, SHG, PDD and COLL.
Lift Portfolio Value With These 5 High Earnings Yield Picks
RGA, JBL, LBRT, CGAU and COLL are a few high earnings yield value stocks that could be good additions to your portfolio now.
Source: https://incomestatements.info
Category: Stock Reports